Philippe Dro brings entrepreneurial expertise and biotech, medtech and pharma industry experience
Successful serial entrepreneur with track record of growing companies, notably for Themis and GlycoVaxyn
Joins at a key juncture in Scenic Biotech’s strategic growth, building its pipeline of genetic modifier drug candidates
AMSTERDAM, The Netherlands, February 02, 2021 / B3C newswire / Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has appointed Dr. Philippe Dro as its independent Chairman. A highly experienced entrepreneur, he replaces Dr. Ulrich Grau who retires from the Board of Directors.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 .
Vaccitech LimitedFebruary 1, 2021 GMT
OXFORD, United Kingdom, Feb. 01, 2021 (GLOBE NEWSWIRE) Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the dosing of the first patient in HBV002. HBV002 is a Phase 1b/2a clinical trial designed to evaluate the safety and preliminary efficacy of VTP-300 both with and without a low-dose anti-PD-1 antibody in patients with chronic hepatitis B (CHB) infection. The study plans to enroll 64 patients in South Korea, Taiwan and the UK.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Experience overseas has proven universities can provide technological innovation that can be commercialised and have a positive impact on economies. One of the best examples of this is Oxford Sciences Innovation, a technology transfer company that was created to fund the university spinout companies.OSI is a major shareholder in Vaccitech, the Oxford University-AstraZeneca Covid-19 vaccine developer. The innovation has also catapulted the Oxford scientist, Prof Sarah Gilbert, who developed the Vaccitech vaccine into fame. This ability to monetise discoveries has been lagging in South Africa, but a University Technology Fund was launched at the beginning of this year and the UTF has managed to secure R230m to help commercialise technology and intellectual property originating from South African universities. The UTF has since its launch invested in five companies: BioCODE, Phagoflux and the Stellenbosch Nanofiber Company from Stellenbosch University, Cape Bio Pharms and Hydrogen Energ
John McHutchison joins the Board of Evox Therapeutics
Highly experienced life sciences executive that brings large pharma and biotech experience
News provided by
Share this article
Share this article
OXFORD, England, Jan. 18, 2021 /PRNewswire/ Evox Therapeutics Ltd ( Evox or the Company ), a leading exosome therapeutics company, today announces that John McHutchison has joined its Board of Directors. John will be joining the Board as the representative for Oxford Sciences Innovation (OSI), one of the Company s major shareholders. John is a highly experienced life sciences executive, with expertise across multiple therapeutic areas, particularly infectious diseases and diseases of the liver and gastrointestinal tract.